Recently, CAR-T therapies targeting multiple B-cell antigens demonstrated the potential to overcome the limitations of CD19 dim or negative expression.12–14 However, it is challenging to broaden this strategy to CAR-T therapy for T-cell leukemia/lymphoma. This evidence concerns the gene CD19 and lymphoma.